title: Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation.
abstract: OBJECTIVE
  To assess transforming growth factor β-receptor II (TGFBRII) protein expression in benign prostatic hyperplasia (BPH) using immunohistochemistry analysis, and to compare the analysis with phenotypic properties.
  
  
  METHODS
  TGFBRII protein expression was profiled using three clinical outcome tissue microarrays (TMAs), sampled from 231 patients who underwent surgery for BPH. Using these TMAs, five inflammatory cell markers were also assessed, including CD3, CD4, CD8, CD20, and CD163. The surgical procedure was open prostatectomy in 95 patients and transurethral resection of the prostate in 136 patients.
  
  
  RESULTS
  TGFBRII protein expression was found in BPH epithelium cells for both basal and secretory cells, as well as in fibromuscular stromal cells. TGFBRII staining was also strong in most of the lymphocytes infiltrating the prostate. TGFBRII stromal staining was found to be significantly associated with prostate volume (P = 0.04), whereas TGFBRII epithelial staining was found to be significantly associated with 5-α-reductase-inhibitor medical therapy received by patients before surgery (P = 0.004). Both stromal and epithelial TGFBRII staining were found to be associated with CD4 T-lymphocyte infiltrate, independently of prostate volume (P < 0.001 and P = 0.002).
  
  
  CONCLUSIONS
  TGFBRII protein expression in BPH is associated with prostate gland volume and with CD4 T-lymphocyte prostatitis. TGFBRII might be a promising therapeutic target to prevent prostate enlargement or even to decrease prostate volume.
authors.affiliation: INSERM, Unité 841, IMRB, Créteil, France. aureliendescazeaud@gmail.com
authors.forename: Aurelien
authors.initials: A
authors.lastname: Descazeaud
authors.forename: Nicolas
authors.initials: N
authors.lastname: Weinbreck
authors.forename: Grégoire
authors.initials: G
authors.lastname: Robert
authors.forename: Francis
authors.initials: F
authors.lastname: Vacherot
authors.forename: Claude C
authors.initials: CC
authors.lastname: Abbou
authors.forename: Francois
authors.initials: F
authors.lastname: Labrousse
authors.forename: Yves
authors.initials: Y
authors.lastname: Allory
authors.forename: Mark A
authors.initials: MA
authors.lastname: Rubin
authors.forename: Alexandre
authors.initials: A
authors.lastname: de la Taille
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism; D018951:Antigens, CD20 / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D017252:CD3 Complex / Q000378:metabolism; D015704:CD4 Antigens / Q000378:metabolism; D016827:CD8 Antigens / Q000378:metabolism; D004847:Epithelial Cells / Q000737:chemistry; D006801:Humans; D008214:Lymphocytes / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011467:Prostate / Q000737:chemistry / Q000473:pathology*; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000378:metabolism* / Q000473:pathology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D011956:Receptors, Cell Surface / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism*; D017154:Stromal Cells / Q000737:chemistry; D020728:Transurethral Resection of Prostate; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D018951:Antigens, CD20; D015214:Antigens, Differentiation, Myelomonocytic; D000098902:CD163 Antigen; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D011956:Receptors, Cell Surface; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II